中国医药科学
中國醫藥科學
중국의약과학
CHINA MEDICINE AND PHARMACY
2015年
5期
83-85
,共3页
噻托溴铵%沙美特罗氟替卡松%支气管哮喘%COPD
噻託溴銨%沙美特囉氟替卡鬆%支氣管哮喘%COPD
새탁추안%사미특라불체잡송%지기관효천%COPD
Tiotropium bromide%Salmeterol xinafoate fluticasone propionate%Bronchial asthma%COPD
目的：探讨噻托溴铵和大剂量沙美特罗氟替卡松联合治疗支气管哮喘合并COPD患者的疗效。方法71例支气管哮喘合并COPD患者随机分为观察组（n=36）和对照组（n=35），两组均给予常规性治疗，在此基础上，给予对照组噻托溴铵与中剂量沙美特罗氟替卡松联合治疗，给予观察组噻托溴铵和大剂量沙美特罗氟替卡松联合治疗，对比两组的疗效。结果两组在治疗前、治疗后1、6、12个月的ACT评分比较，差异无统计学意义（P＞0.05）。治疗1年后，观察组在FEV1%预计值、FEV1增加量、△PEF、急性加重发作时间、发作间隔时间、CAT评分等均显著地优于对照组（P＜0.05）。结论采取噻托溴铵和大剂量沙美特罗替卡松联合应用治疗能够显著地改善肺功能，缓解急性加重病症，提高生活质量，值得推广。
目的：探討噻託溴銨和大劑量沙美特囉氟替卡鬆聯閤治療支氣管哮喘閤併COPD患者的療效。方法71例支氣管哮喘閤併COPD患者隨機分為觀察組（n=36）和對照組（n=35），兩組均給予常規性治療，在此基礎上，給予對照組噻託溴銨與中劑量沙美特囉氟替卡鬆聯閤治療，給予觀察組噻託溴銨和大劑量沙美特囉氟替卡鬆聯閤治療，對比兩組的療效。結果兩組在治療前、治療後1、6、12箇月的ACT評分比較，差異無統計學意義（P＞0.05）。治療1年後，觀察組在FEV1%預計值、FEV1增加量、△PEF、急性加重髮作時間、髮作間隔時間、CAT評分等均顯著地優于對照組（P＜0.05）。結論採取噻託溴銨和大劑量沙美特囉替卡鬆聯閤應用治療能夠顯著地改善肺功能，緩解急性加重病癥，提高生活質量，值得推廣。
목적：탐토새탁추안화대제량사미특라불체잡송연합치료지기관효천합병COPD환자적료효。방법71례지기관효천합병COPD환자수궤분위관찰조（n=36）화대조조（n=35），량조균급여상규성치료，재차기출상，급여대조조새탁추안여중제량사미특라불체잡송연합치료，급여관찰조새탁추안화대제량사미특라불체잡송연합치료，대비량조적료효。결과량조재치료전、치료후1、6、12개월적ACT평분비교，차이무통계학의의（P＞0.05）。치료1년후，관찰조재FEV1%예계치、FEV1증가량、△PEF、급성가중발작시간、발작간격시간、CAT평분등균현저지우우대조조（P＜0.05）。결론채취새탁추안화대제량사미특라체잡송연합응용치료능구현저지개선폐공능，완해급성가중병증，제고생활질량，치득추엄。
ObjectiveTo investigate effect of tiotropium bromide and large dose of salmeterol xinafoate fluticasone propionate in patients with bronchial asthma combined with COPD.Methods71 patients of bronchial asthma combined with COPD were randomly divided into observation group(n=36 cases)and control group(n=35 cases). The two groups were given conventional treatment.The control group was given tiotropium bromide and moderate dose of salmeterol xinafoate fluticasone propionate,while the observation group was given tiotropium bromide and large dose of salmeterol xinafoate fluticasone propionate.Efficacy of the two groups was compared.Results ACT score of pre-treatment,and 1 month,6 month,12 month in two groups had no significant difference(P>0.05).After 1 years of treatment,FEV1% estimates,FEV1 increase,Delta PEF,acute exacerbation onset time,interval time,CAT score of observation group were significantly better than that of the control group(P<0.05).Conclusion Tiotropium bromide and large dose of salmeterol xinafoate fluticasone propionate in patients with bronchial asthma combined with COPD can significantly improve lung function,relieve the acute exacerbation of symptoms,improve the quality of life,and is worthy of promotion.
